CRP identifies homeostatic immune oscillations in cancer patients: A potential treatment targeting tool?

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages

  Coventry, Brendon J ^a   Ashdown, Martin L ^b   Quinn, Michael A ^b   Markovic, Svetomir N ^c   Yatomi Clarke, Steven L ^d   Robinson, Andrew P ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MAYO CLINIC CANCER CENTER   (United States)

^d Berbay Biosciences   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; TUMOR MARKER; DIAGNOSTIC AGENT;

AGGLUTINATION TEST; AUTOIMMUNITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNODIFFUSION; IMMUNOREGULATION; INFLAMMATION; MELANOMA; OSCILLATION; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; TISSUE INJURY; TREATMENT RESPONSE; VACCINATION; BLOOD; IMMUNOLOGY; METABOLISM; NEOPLASM; PERIODICITY;

C-REACTIVE PROTEIN; HOMEOSTASIS; HUMANS; INFLAMMATION; NEOPLASMS; PERIODICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 72549117233     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-102     Document Type: Review

References (35)

1. Rudnicka AR, Rumley A, Lowe GDO, Strachan DP. Diurnal, Seasonal, and Blood-Processing Patterns in Levels of Circulating Fibrinogen, Fibrin D-Dimer, C-Reactive Protein, Tissue Plasminogen Activator, and von Willebrand Factor in a 45-Year-Old Population. Circulation 2007, 115:996-1003. 10.1161/CIRCULATIONAHA.106.635169, 17296859.
2. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001, 47:426-430.
3. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003, 111(12):1805-12. Review, 161431, 12813013.
4. Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology, gene expression, and host defense function. Immunol Res 1997, 16(2):127-36. 10.1007/BF02786357, 9212359.
5. Das T, Sen AK, Kempf T, Pramanik SR, Mandal C, Mandal C. Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem J 2003, 373(Pt 2):345-55. Erratum in: Biochem J. 2003 Sep 15, 374 (Pt 3): 807, 10.1042/BJ20021701, 1223501, 12693993.
6. Tillett WS, Francis T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930, 52:561-585. 10.1084/jem.52.4.561, 2131884, 19869788.
7. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002, 4(3):250-5. 10.1007/s11912-002-0023-1, 11937016.
8. Deichmann M, Kahle B, Moser K, Wacker J, Wüst K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 2004, 91(4):699-702. 2364774, 15280926.
9. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004, 291(5):585-90. 10.1001/jama.291.5.585, 14762037.
10. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 2007, 109(4):933-41.
11. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008, 14(3):710-4. 10.1158/1078-0432.CCR-07-1044, 18245530.
12. Williams DK, Muddiman C. Absolute Quantification of C-Reactive Protein in Human Plasma Derived from Patients with Epithelial Ovarian Cancer Utilizing Protein Cleavage Isotope Dilution Mass Spectrometry J. Proteome Res 2009, 8(2):1085-1090.
13. Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, Jost E. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie 2008, 31(12):665-70. 10.1159/000165054, 19060504.
14. Chiu HM, Lin JT, Chen TH, Lee YC, Chiu YH, Liang JT, Shun CT, Wu MS. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasms in men. Am J Gastroenterol 2008, 103(9):2317-25. 10.1111/j.1572-0241.2008.01952.x, 18844617.
15. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, Ben-Shlomo Y, Ebrahim S, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009, 20(1):15-26. 10.1007/s10552-008-9212-z, 18704713.
16. Groblewska M, Mroczko B, Wereszczyska-Siemiatkowska U, Kedra B, Lukaszewicz M, Baniukiewicz A, Szmitkowski M. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 2008, 46(10):1423-8. 10.1515/CCLM.2008.278, 18844497.
17. Sawamura M, Yamaguchi S, Murakami H, Kitahara T, Itoh K, Maehara T, Kawada E, Matsushima T, Tamura J, Naruse T. Cyclic haemopoiesis at 7- or 8-day intervals. Br J Haematol 1994, 88(1):215-8. 10.1111/j.1365-2141.1994.tb05004.x, 7528529.
18. Guimond M, Fry TJ, Mackall CL. Cytokine signals in T-cell homeostasis. J Immunother 2005, 28(4):289-94. 10.1097/01.cji.0000165356.03924.e7, 16000945.
19. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother 2008, 58(8):1219-28. 10.1007/s00262-008-0628-9, 19052741.
20. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP. Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?. Nat Clin Pract Oncol 2006, 3(12):668-681.
21. Khaled AR, Bulavin DV, Kittipatarin C, Li WQ, Alvarez M, Kim K, Young HA, Fornace AJ, Durum SK. Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biol 2005, 169(5):755-63. 10.1083/jcb.200409099, 2171622, 15928203.
22. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffe EM. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005, 201(10):1591-602. 10.1084/jem.20042167, 2212915, 15883172.
23. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004, 117(2):265-77. 10.1016/S0092-8674(04)00335-6, 15084263.
24. Koenig W. Increased concentrations of C-Reactive Protein and IL-6, but not IL-18 are independently associated with incident coronary events in middle-aged men and women. Arterioscler Thromb Vasc Biol 2006, 12:2745-2751.
25. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease. Ann Intern Med 2006, 145(1):35-42.
26. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005, 288(5):H2031-41. 10.1152/ajpheart.01058.2004, 15653761.
27. Danesh J. C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. New England Journal of Medicine 2004, 350(14):1387-1397. 10.1056/NEJMoa032804, 15070788.
28. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006, 440:1217-1221. 10.1038/nature04672, 16642000.
29. Dehghan A. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 2007, 56:872. 10.2337/db06-0922, 17327459.
30. Pradhan AD. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334. 10.1001/jama.286.3.327, 11466099.
31. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003, 348(10):891-899. 10.1056/NEJMoa021735, 12621133.
32. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009, 27(13):2217-24. 10.1200/JCO.2008.19.8440, 19289618.
33. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007, 56(5):641-8. 10.1007/s00262-006-0225-8, 16960692.
34. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success?. J Clin Invest 2008, 118(6):1991-2001. 10.1172/JCI35180, 2396905, 18523649.
35. Darrasse-Jèze G, Bergot A-S, Durgeau A, Billiard F, Salomon BL, Cohen JL, Bellier B, Podsypanina K, Klatzmann D. Tumor emergence is sensed by self-specific CD44 hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 2009, 119(9):2648-62. 2735938, 19652360.